The value of Real World Evidence (RWE) is well known to many stakeholders, but its full potential for market access and regulatory submission can surprise even those who are familiar with its uses. Evidence-based cost-effectiveness models can showcase the true economic value of a product during market access, and sometimes even aid with regulatory submissions. At Cytel, we generate evidence which complements traditional randomized clinical trials, accelerates submissions, expands indications, proves value, and supports health-economic decision-making.
At Virtual ISPOR Europe 2021, to be held 30 November – 3 December, our Global team of HEOR and RWE experts will present across new therapeutic approaches and demonstrate a vast range of methods and techniques. Avail this opportunity to learn how to maximize the evidence you need to go from research to market, overcome regulatory hurdles and support payer approval.
We Invite you to attend the following ISPOR Europe 2021 On Demand Podium Sessions:
P15: Transcatheter Versus Surgical Aortic Valve Replacement - a Real-World Comparison of Clinical Outcomes Based on a German Claims Dataset
Cytel Contributors: Fraence Hardtstock and Thomas Wilke
Overview: The presenters discuss a study conducted to describe clinical outcomes after transcatheter aortic valve implantation (TAVI) and surgical aortic valve implantation (SAVR). TAVI has become the new standard of care in recent years and has replaced the classic aortic valve replacement, specifically in more fragile patients.
P21: Social Distancing and Trends in Influenza Hospitalization during the COVID-19 Outbreak: A Difference-in-Difference Analysis of German Claims Data
Cytel Contributors: Scarlette Pacis, Thomas Wilke and Marco Ghiani
Overview: As COVID-19 spread worldwide, indicators of influenza activity in the Northern Hemisphere began to decline by mid-to-late February. In Germany, federal lockdown measures were introduced to contain the outbreak on March 22, 2020. A study was conducted using claims data from AOK PLUS to examine the trend of influenza hospitalizations in 2020 compared to 2019.
P44: Novel and Existing Flexible Survival Methods for Network Meta-Analyses
Cytel Contributors: Andrea Garcia, Andre Verhoek, S. Van Beekhuizen and Bart Heeg
Overview: The NICE Decision Support Unit recently published technical support document 21, focusing on flexible survival methods and considering excess mortality. In a study, these flexible survival methods were researched by assessing the effect of treatment on the different parameters of the distributions and the implementation of these flexible excess survival models in network meta-analyses (NMA).
P45: The Use of Historical Clinical Trial Data to Inform Survival Extrapolation
Cytel Contributors: Ha Anh Pham, David Smalbrugge, Florint Kroi and Bart Heeg
Overview: Standard parametric distributions are commonly used for the extrapolation of survival data in cost-effectiveness analyses. However, survival data is often immature and uncertainty remains around the survival extrapolations. Mature historical data can be used to better predict survival beyond trial data. The study presented assessed two methods to incorporate historical data in the extrapolation of immature survival data.
P64: Evaluating the Impact of the COVID-19 Pandemic on Mortality after Myocardial Infarctions Hospitalization in Germany
Cytel Contributors: Julia Krieger, Fraence Hardtstock and Thomas Wilke
Overview: It was hypothesized that COVID-19 lockdown measures led to later admission of myocardial infarction (MI) patients to hospitals and, consequently, higher average case severity and mortality. The presenters discuss a study conducted to compare MI-associated mortality between COVID-19 lockdown and pre-COVID-19 periods.
Click below to download our full list of sessions at Virtual ISPOR Europe 2021.
About the Author of Blog:
Mansha Sachdev specializes in content creation and knowledge management. She holds an MBA degree and has 11 years of experience in handling various facets of marketing, across industries. At Cytel, Mansha is a Content Marketing Manager and is responsible for producing informative content that is related to the pharmaceutical and medical devices industries.